SG11201407667UA - MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD - Google Patents

MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Info

Publication number
SG11201407667UA
SG11201407667UA SG11201407667UA SG11201407667UA SG11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA SG 11201407667U A SG11201407667U A SG 11201407667UA
Authority
SG
Singapore
Prior art keywords
plgf
sflt
endoglin
preeclampsia
rule
Prior art date
Application number
SG11201407667UA
Inventor
Martin Hund
Maria Schoedl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407667U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP12183508.6A external-priority patent/EP2706359A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201407667UA publication Critical patent/SG11201407667UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201407667UA 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD SG11201407667UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173886 2012-06-27
EP12183508.6A EP2706359A1 (en) 2012-09-07 2012-09-07 Means and methods applying sFlt-1/PlGF or Endoglin/PlGF ratio to rule-out onset of preeclampsia within a certain time period
PCT/EP2013/063115 WO2014001244A1 (en) 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Publications (1)

Publication Number Publication Date
SG11201407667UA true SG11201407667UA (en) 2015-02-27

Family

ID=48741083

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407667UA SG11201407667UA (en) 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Country Status (12)

Country Link
US (1) US20150338415A1 (en)
EP (1) EP2867670B1 (en)
JP (1) JP5937756B2 (en)
KR (2) KR101996123B1 (en)
CN (1) CN104412107B (en)
BR (1) BR112014029233A8 (en)
CA (1) CA2871878C (en)
ES (1) ES2681238T3 (en)
HK (1) HK1208264A1 (en)
MX (1) MX356775B (en)
SG (1) SG11201407667UA (en)
WO (1) WO2014001244A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (en) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Gene expression profile as a marker of endometrial receptivity
WO2014135488A1 (en) 2013-03-04 2014-09-12 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
CA2936883C (en) * 2014-01-24 2022-06-28 Martin Hund Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
CN106662589B (en) * 2014-03-21 2019-07-30 艾基诺米公司 The early detection of pre-eclampsia
JP2015207111A (en) * 2014-04-18 2015-11-19 ソニー株式会社 Examination server, examination method, and examination system
SI3569697T1 (en) 2014-06-17 2022-05-31 Asherman Therapy, S.L. Stem cell therapy in endometrial pathologies
EP3423834B1 (en) * 2016-02-29 2022-08-17 Roche Diagnostics GmbH Igfbp-7 as a marker in preeclampsia
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
MX2020002788A (en) 2017-09-13 2020-09-14 Progenity Inc Preeclampsia biomarkers and related systems and methods.
WO2020016441A1 (en) * 2018-07-20 2020-01-23 Roche Diagnostics Gmbh Prediction of preeclampsia based on igfbp-7
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN114200137B (en) * 2020-09-16 2023-09-01 四川大学 Ratio immunoassay method with commercial magnetic beads as internal standard

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916606B2 (en) * 1986-04-30 2005-07-12 Bioveris Corporation Electrochemiluminescent assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US7141436B2 (en) * 1999-11-03 2006-11-28 Science And Technology Corp. Immunoassay and reagents and kits for performing the same
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
OA12890A (en) 2002-07-19 2006-10-13 Beth Israel Hospital Methods of diagnosing and treating pre-eclampsia or eclampsia.
EP1664797B1 (en) * 2003-09-23 2015-11-11 The General Hospital Corporation Screening for preeclampsia
MX2007003522A (en) * 2004-09-24 2007-06-11 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy.
ES2475975T3 (en) 2004-12-21 2014-07-11 Yale University Preeclampsia diagnosis
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
DE602007012272D1 (en) * 2006-09-07 2011-03-10 Merck Sharp & Dohme DIFLUORATED PIPERIDINE FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED ACCIDENTS
EP2120573A4 (en) * 2007-02-12 2011-05-25 Merck Sharp & Dohme Piperidine derivatives
US20090068683A1 (en) * 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
WO2009089286A1 (en) 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
CN110187121B (en) 2008-10-31 2022-07-01 耶鲁大学 Methods and compositions for the detection and treatment of preeclampsia
WO2010059952A1 (en) * 2008-11-20 2010-05-27 Perkinelmer Health Sciences, Inc. Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
CN102893156A (en) * 2009-12-21 2013-01-23 爱尔兰国立科克大学 Detection of risk of pre-eclampsia
CA2793487A1 (en) * 2010-04-13 2011-10-20 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
EP2383579A1 (en) * 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, cardiac troponins and natriuretic peptides in the recognition of therapy with HER-2 inhibitors
EP2490027A1 (en) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1

Also Published As

Publication number Publication date
CA2871878C (en) 2021-08-10
JP2015525870A (en) 2015-09-07
JP5937756B2 (en) 2016-06-22
KR20160116060A (en) 2016-10-06
ES2681238T3 (en) 2018-09-12
CA2871878A1 (en) 2014-01-03
EP2867670A1 (en) 2015-05-06
EP2867670B1 (en) 2018-05-30
US20150338415A1 (en) 2015-11-26
KR20150023063A (en) 2015-03-04
MX356775B (en) 2018-06-13
BR112014029233A2 (en) 2017-06-27
HK1208264A1 (en) 2016-02-26
MX2014014463A (en) 2015-02-12
BR112014029233A8 (en) 2019-01-29
CN104412107A (en) 2015-03-11
KR101996123B1 (en) 2019-07-03
CN104412107B (en) 2018-06-08
AU2013283540A8 (en) 2014-11-20
WO2014001244A1 (en) 2014-01-03
AU2013283540A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
HK1208264A1 (en) Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf
HK1203855A1 (en) Threads of cross-linked hyaluronic acid and methods of use thereof
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
EP2850745A4 (en) Balloon clumping to provide bandwidth requested in advance
EP2991588A4 (en) Prosthetic tissue valves and methods for anchoring same to cardiovascular structures
EP2910238A4 (en) Hyaluronic acid gel and method for producing same
GB2508574B (en) Improvements in and relating to the control of ions
HK1212251A1 (en) Topical compositions and methods of use
EP2888590A4 (en) Antibodies to olanzapine and use thereof
HK1220520A1 (en) Method and system to predict response to pain treatments
EP2906942A4 (en) Processor-based analysis system and method
EP2820881A4 (en) Method and system for early termination of transmissions in response to ack of early decoding
EP2824182A4 (en) Method for stimulating t cell and use thereof
EP2870527A4 (en) System and related method to facilitate process control
EP2991627A4 (en) Blood substitute composition and method of use
EP2821504A4 (en) Method for designating disease relating to amount of tdp-43 existing in cells
HK1214154A1 (en) Topical steroid composition and method
HK1224175A1 (en) Composition for use in reducing scab formation and promoting healing
EP2828649A4 (en) Systems and methods to determine and monitor changes in rail conditions
BR112016014485A2 (en) method of achieving a color change in a cosmetic composition applied to a human integument
EP2922413A4 (en) Compostions of low sodium salt and methods of making and using
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
EP2820561A4 (en) Method and system for using neuroscience to predict consumer preference
GB2509033B (en) Composition for coloring skin and method for coloring skin
GB2512996B (en) System and method of arbitrating access to interconnect